PDF《Content》

6 We would continue adhering to academic promotion as the core and further enrich and expand marketing channels. Meanwhile, we will also further enrich our product lines and continuously enhance the internal driver and competitiveness in respect of the development of the Company, so that we can have broader space for development and greater development benefits in anti-virus, endocrine, metabolic and digestive diseases and cardiovascular diseases prevention and treatment and other areas. II. BUSINESS REVIEW Overall sales performance In the first half of 2017, our revenue reached RMB662.3 million, representing an increase of 19.2% as compared to the same period of 2016. Revenue from Kewei products reached RMB556.7 million........